Brought to you by 
Israeli biotech Sol-Gel nets $80.2mm in Nasdaq IPO
12 Feb 2018
Executive Summary
Five months after filing, dermatology-focused Israeli biotech Sol-Gel Technologies Ltd. (topical drug therapies) netted $80.2mm in a Nasdaq initial public offering of 7.2mm ordinary shares, including the overallotment, at $12. It had originally planned to offer 5mm shares at an $11-13 range.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
- Topical Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Israeli biotech Sol-Gel nets $80.2mm in Nasdaq IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice